FibroGen Prepares to Share Q4 and Year-End Results for 2024

Author: Olivia Taylor Updated: 03-03-2025 04:50 PM

FibroGen to Announce Financial Performance

FibroGen, Inc. (NASDAQ: FGEN), a prominent biopharmaceutical firm, is preparing to unveil its financial results for the fourth quarter and the full year of 2024. The announcement is set for Monday, March 17, taking place after the market closes. This session will provide a comprehensive overview of the company’s financial standing and corporate advancements.

Insights from the Conference Call

Following the financial report, FibroGen will conduct a conference call scheduled for 5:00 PM Eastern Time. This call is an opportunity for the management team to delve deeper into the financial outcomes and discuss the company’s future direction. Participants will have the opportunity to engage in a live Q&A session following the main presentation, making it an interactive experience for stakeholders.

Accessing the Call

Investors and interested parties can listen to the conference call through a live audio webcast. To access this, registration is required. The call can also be accessed via phone, with dial-in details provided upon registration. Following the live event, a replay will be offered on FibroGen’s website for a limited duration, ensuring that those unable to attend the live session can still gain valuable insights.

About FibroGen

FibroGen, Inc. focuses on pioneering therapies in the challenges of cancer biology and anemia treatment. The company’s flagship product, Roxadustat (also known as EVRENZO™), has garnered regulatory approvals in various regions, including China, Europe, and Japan, specifically for treating anemia in patients with chronic kidney disease (CKD), both on dialysis and not. FibroGen is also exploring additional applications for Roxadustat in conditions like lower-risk myelodysplastic syndrome (LR-MDS).

Innovative Treatments Under Development

Moreover, FibroGen is advancing FG-3246 (or FOR46), a groundbreaking antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer treatment. This innovative approach showcases FibroGen's commitment to addressing unmet medical needs in oncology and related fields, and it also encompasses the development of FG-3180, a CD46-targeted PET biomarker.

Stay Updated with FibroGen

For more detailed information about the company’s advancements and to access the latest updates regarding their therapies, interested individuals can visit FibroGen’s official website. This platform serves as a hub for learning about ongoing clinical trials and any new announcements pertaining to their product pipeline.

Frequently Asked Questions

What financial results will FibroGen announce?

FibroGen will announce its fourth quarter and full year 2024 financial results, offering insights into its corporate performance.

When is the conference call scheduled?

The conference call is scheduled for March 17 at 5:00 PM Eastern Time, following the financial results announcement.

How can I listen to the conference call?

Investors can access the conference call through a live audio webcast, with phone access available after registering in advance.

What is Roxadustat?

Roxadustat is FibroGen's primary product, approved for treating anemia in chronic kidney disease patients across multiple countries.

What other treatments is FibroGen developing?

FibroGen is also working on FG-3246, an ADC for prostate cancer, and FG-3180, a PET biomarker targeting CD46.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.